SUV39H1-inactivated CAR T cells

SUV39H1-inactivated CAR T cells are an experimental cell therapy being developed by Mnemo Therapeutics in collaboration with Institut Curie. This therapy utilizes CRISPR-Cas9 gene editing to disrupt the *SUV39H1* gene, which encodes a histone-3 lysine-9 (H3K9) methyltransferase. By ablating SUV39H1, the cells undergo epigenetic reprogramming that prevents the silencing of genes associated with T cell memory and stemness. This modification results in CAR T cells with enhanced persistence, improved long-term survival, and a reduced susceptibility to T cell exhaustion compared to conventional CAR T products. Preclinical data have demonstrated that these modified cells provide sustained protection against tumor relapses in various models, including lung adenocarcinoma, ovarian cancer, prostate cancer, and leukemia, regardless of whether the CAR construct utilizes CD28 or 4-1BB costimulatory domains.

Other names

SUV39H1-KO CAR T cellsSUV-39H1-KO CAR T cellsSUV 39H1-KO CAR T cellsSUV39H1-deficient CAR T cellsSUV-39H1-deficient CAR T cellsSUV 39H1-deficient CAR T cellsSUV39H1-deleted CAR T cellsSUV-39H1-deleted CAR T cellsSUV 39H1-deleted CAR T cells